Contributions
Abstract: EP1645
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Objective: To compare efficacy between natalizumab (NTZ) and fingolimod (FTY) in active relapsing remitting multiple sclerosis (RRMS)
Methods: BEST-MS was a French multicentric study (ClinicalTrials.gov Identifier: NCT01981161) with prospective data collection involving patients with active RRMS who started either NTZ or FTY. Treatment choice was patient's and physician's discretion. Last patient was recruited by September 2016.
Efficacy was assessed by clinical (EDSS, relapses) and MRI parameters (number of new T2 lesions, number of gadolinium enhancing lesions) after 12 months of therapy, and compared between treatment groups. We present data about MRI findings.
Results: 224 patients were included in 10 MS centers (NTZ : 111 ; FTY : 113). Sex ratio was 3.15, mean age was 30 [12-62]. Mean disease duration was 6 years. Baseline EDSS was 2.4 [0-6.5] and mean number of relapses during the 12 months preceding initiation of treatment was 1.4 [0-3]. To date, we collected both initial and 1-year MRI data for 66 patients.
Comparison between treatment groups showed that NTZ patients had a shorter disease duration (3.4 vs 7.4 months; p< 0.05) and a higher relapse rate before treatment initiation (1.6 vs 1.1; p< 0.05). Regarding MRI, there was no significant difference between groups at baseline.
After 12 months, mean number of new T2 lesions was 0.45 [0-5], without any difference between treatment groups. Mean number of gadolinium enhancing lesions was 0.1 [0-3]. There was a significant lower number of gadolinium enhancing lesions in patients treated with NTZ (0.06 vs 0.18; p< 0.05).
Discussion: Regarding MRI parameters, NTZ seems to be more effective than FTY in reducing the number of gadolinium enhancing lesions.
Further analysis will be performed to compare clinical efficacy between treatment groups
Conclusion: We present MRI results of BEST-MS study. Results suggest a higher efficacy of NTZ compared to FTY on radiological parameters.
Disclosure:
Patrick Vermersch reports Honoraria and consulting fees from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche, Servier, Medday and Almirall, Research supports from Biogen, Bayer, Novartis, Sanofi-Genzyme, Roche and Merck-Serono
Dr Sandrine Wiertlewski received consultancy fees, speaker fees, honoraria and clinical research grants from Biogen-Idec, Novartis, Genzyme, Sanofi-Aventis and Teva, Roche
David Brassat received consulting fees and speaker honororia from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday
David Laplaud received honoraria and consulting from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday. Research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Medday.
Dr Defer received personal compensation for serving on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi Aventis, Genzyme and Teva Pharmaceutical Industries Ltd He has received funding for travel and/or speaker honoraria from Merck Serono, Biogen, Guerbet, Sanofi Aventis, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd. His institution received grants supporting research in his department from Merck Serono, Biogen, Sanofi Aventis and Novartis
Pr Brochet has received consultancy fees, speaker fees, research grants (non-personal), or honoraria from Novartis, Biogen-Idec, Merck, Bayer Schering, Roche, Medday, Bayer, Actelion, Teva and Genzyme Sanofi.
Dr Berger received Research supports from Biogen, honoraria and consulting fees from Novartis, Sanofi, Biogen, Genzyme
Guillaume Mathey has received paid travel accommodations from Biogen, Merck, Teva, Novartis, and Sanofi
Hélène Zéphir received fees for consulting or lectures, and invitations for national and international congresses from BIOGEN IDEC, MERCK, TEVA, GENZYME, SANOFI, NOVARTIS and BAYER, as well as research support from TEVA and ROCHE, academic research grants from Académie de Médecine, LFSEP, and ARSEP Foundation
Dr Cohen reports participation to advisory boards for Biogen, Novartis, Roche and
Ad Scientam, with no relation to this study.
Other authors report no disclosures related to this work
Abstract: EP1645
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Objective: To compare efficacy between natalizumab (NTZ) and fingolimod (FTY) in active relapsing remitting multiple sclerosis (RRMS)
Methods: BEST-MS was a French multicentric study (ClinicalTrials.gov Identifier: NCT01981161) with prospective data collection involving patients with active RRMS who started either NTZ or FTY. Treatment choice was patient's and physician's discretion. Last patient was recruited by September 2016.
Efficacy was assessed by clinical (EDSS, relapses) and MRI parameters (number of new T2 lesions, number of gadolinium enhancing lesions) after 12 months of therapy, and compared between treatment groups. We present data about MRI findings.
Results: 224 patients were included in 10 MS centers (NTZ : 111 ; FTY : 113). Sex ratio was 3.15, mean age was 30 [12-62]. Mean disease duration was 6 years. Baseline EDSS was 2.4 [0-6.5] and mean number of relapses during the 12 months preceding initiation of treatment was 1.4 [0-3]. To date, we collected both initial and 1-year MRI data for 66 patients.
Comparison between treatment groups showed that NTZ patients had a shorter disease duration (3.4 vs 7.4 months; p< 0.05) and a higher relapse rate before treatment initiation (1.6 vs 1.1; p< 0.05). Regarding MRI, there was no significant difference between groups at baseline.
After 12 months, mean number of new T2 lesions was 0.45 [0-5], without any difference between treatment groups. Mean number of gadolinium enhancing lesions was 0.1 [0-3]. There was a significant lower number of gadolinium enhancing lesions in patients treated with NTZ (0.06 vs 0.18; p< 0.05).
Discussion: Regarding MRI parameters, NTZ seems to be more effective than FTY in reducing the number of gadolinium enhancing lesions.
Further analysis will be performed to compare clinical efficacy between treatment groups
Conclusion: We present MRI results of BEST-MS study. Results suggest a higher efficacy of NTZ compared to FTY on radiological parameters.
Disclosure:
Patrick Vermersch reports Honoraria and consulting fees from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche, Servier, Medday and Almirall, Research supports from Biogen, Bayer, Novartis, Sanofi-Genzyme, Roche and Merck-Serono
Dr Sandrine Wiertlewski received consultancy fees, speaker fees, honoraria and clinical research grants from Biogen-Idec, Novartis, Genzyme, Sanofi-Aventis and Teva, Roche
David Brassat received consulting fees and speaker honororia from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday
David Laplaud received honoraria and consulting from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday. Research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Medday.
Dr Defer received personal compensation for serving on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi Aventis, Genzyme and Teva Pharmaceutical Industries Ltd He has received funding for travel and/or speaker honoraria from Merck Serono, Biogen, Guerbet, Sanofi Aventis, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd. His institution received grants supporting research in his department from Merck Serono, Biogen, Sanofi Aventis and Novartis
Pr Brochet has received consultancy fees, speaker fees, research grants (non-personal), or honoraria from Novartis, Biogen-Idec, Merck, Bayer Schering, Roche, Medday, Bayer, Actelion, Teva and Genzyme Sanofi.
Dr Berger received Research supports from Biogen, honoraria and consulting fees from Novartis, Sanofi, Biogen, Genzyme
Guillaume Mathey has received paid travel accommodations from Biogen, Merck, Teva, Novartis, and Sanofi
Hélène Zéphir received fees for consulting or lectures, and invitations for national and international congresses from BIOGEN IDEC, MERCK, TEVA, GENZYME, SANOFI, NOVARTIS and BAYER, as well as research support from TEVA and ROCHE, academic research grants from Académie de Médecine, LFSEP, and ARSEP Foundation
Dr Cohen reports participation to advisory boards for Biogen, Novartis, Roche and
Ad Scientam, with no relation to this study.
Other authors report no disclosures related to this work